Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL
Links shared publicly online about this topic.
- 1,795total visits
Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL
Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.
View full resource at news-medical.net
Tags: Kidney Disease, Dialysis, End-Stage Renal Disease, Disease and Condition, Phase 3 Clinical Trial, Aranesp, Amgen, Nephrology
Most Recently Shared on August 26, 2009 at 1:59 pm By:
Stroke News: Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobi.. http://twurl.nl/zpvhnu
Advertisement
